ReviewEuropean urology focus2022
Liquid Biopsy for Prostate and Bladder Cancer: Progress and Pitfalls.
Review in European urology focus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.British journal of cancer · 2026Article
- Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques.Diseases (Basel, Switzerland) · 2026Review
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Ultrasound radiomics model based on grayscale transrectal ultrasound-guided biopsy for diagnosing prostate cancer and predicting distant metastasis.International urology and nephrology · 2025Article
- A scoping review of factors influencing the implementation of liquid biopsy for cancer care.Journal of experimental & clinical cancer research : CR · 2025Article
- Improving platelet-RNA-based diagnostics: a comparative analysis of machine learning models for cancer detection and multiclass classification.Molecular oncology · 2024Article
- Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.Frontiers in oncology · 2024Review
- Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer.International journal of molecular sciences · 2023Review
- Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".International urology and nephrology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary liquid biopsy (LB) tests have contributed to reducing overtreatment and improving the detection of bladder and prostate cancer. Circulating tumor cells, DNA, and RNA are the focus of next-generation blood-based LB tests. These tests aim to stratify risk according to the detection of resistance and recurrence markers in patients with metastatic disease. The costs, lack of standardization, reimbursement challenges, and specialized workflows associated with characterization of blood-derived biomarkers are the primary barriers to their clinical implementation. This review provides an overview of the successes and pitfalls of LB-based tests for bladder and prostate cancer. PATIENT SUMMARY: Urinary and blood-based liquid biopsy tests are minimally invasive and highly efficacious in detecting clinically significant cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.